Role of the epithelial-mesenchymal transition in bladder cancer: From prognosis to therapeutic target

Korean Journal of Urology

Volumn 54, Issue 10, 2013, Pages 645-650

  Yun, Seok Joong ^a   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

Epithelial mesenchymal transition; Prognosis; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; BETA CATENIN; CALGRANULIN B; CISPLATIN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBRONECTIN; MICRORNA 141; MICRORNA 192; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; NERVE CELL ADHESION MOLECULE; P CADHERIN; PLAKOGLOBIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UVOMORULIN; VIMENTIN;

BLADDER CANCER; BLADDER METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; METABOLIC INHIBITION; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR INVASION; TUMOR RECURRENCE;

EID: 84886296996     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2013.54.10.645     Document Type: Review

References (50)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer sta-tistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from sev-en EORTC trials. Eur Urol 2006;49:466-5.
4. Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's urology. 8th ed. Philadelphia: Saunders; 2002. p. 2750-1.
5. Messing EM. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh's urology. 9th ed. Philadelphia: Saunders; 2007:17-2430.
6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
7. Savagner P, Boyer B, Valles AM, Jouanneau J, Thiery JP. Modulations of the epithelial phenotype during embryogenesis and cancer progression. Cancer Treat Res 1994;71:229-49.
8. Thiery JP. Epithelial-mesenchymal transitions in tumour prog-ression. Nat Rev Cancer 2002;2:442-54.
9. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005;65:5996-6000.
10. van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 2012;10:995-1009.
11. Chen J, Han Q, Pei D. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol 2012;4:66-9.
12. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial pheno-type? Nat Rev Cancer 2007;7:415-28.
13. Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol 2000;299:551-72.
14. Rangel MC, Karasawa H, Castro NP, Nagaoka T, Salomon DS, Bianco C. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer. Am J Pathol 2012;180: 2188-200.
15. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.
16. Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008;4:835-50.
17. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, et al. Molecular and pathological signatures of epi-thelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008;130:481-94.
18. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28:15-33.
19. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor re-ceptor-2. Cancer Res 2006;66:11271-8.
20. Medici D, Hay ED, Goodenough DA. Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-in-duced epithelial-mesenchymal transition. Mol Biol Cell 2006;17:1871-9.
21. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003;278:21113-23.
22. Choi J, Park SY, Joo CK. Transforming growth factor-beta1 re-presses E-cadherin production via slug expression in lens epi-thelial cells. Invest Ophthalmol Vis Sci 2007;48:2708-18.
23. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family de-termines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.
24. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.
25. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846-54.
26. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
27. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44.
28. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mes-enchymal transition. FASEB J 2010;24:1838-51.
29. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol 2010;184:423-31.
30. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, et al. The expression of Twist has an impact on surviv-al in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009;27:268-76.
31. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or meta-static bladder and prostate cancers. Urol Oncol 2010;28:473-9.
32. Yu Q, Zhang K, Wang X, Liu X, Zhang Z. Expression of tran-scription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res 2010;29:119.
33. Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, et al. Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urol Oncol 2010;28:591-6.
34. Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, et al. Novel ZEB1 expression in bladder tumorigenesis. BJU Int 2011;107:656-63.
35. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal tran-sition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009;15: 5060-72.
36. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011;128:1327-34.
37. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, et al. The p63 protein isoform ΔNp63α inhibits epithelial-mesen-chymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem 2013;288:3275-88.
38. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic bio-markers of bladder cancer. Int J Oncol 2012;41:1871-8.
39. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 2012;10:106-13.
40. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, et al. Identification and prognostic sig-nificance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13: 1685-94.
41. Paliwal P, Arora D, Mishra AK. Epithelial mesenchymal tran-sition in urothelial carcinoma: twist in the tale. Indian J Pathol Microbiol 2012;55:443-9.
42. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-86.
43. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing li-gand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004;64:3386-90.
44. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010;9:3254-66.
45. Gao F, Zhao ZL, Zhao WT, Fan QR, Wang SC, Li J, et al. miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 2013;431:610-6.
46. Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, et al. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res 2013;73:5416-25.
47. Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollings-worth MA, Wheelock MJ, et al. ADH-1 suppresses N-cadher-in-dependent pancreatic cancer progression. Int J Cancer 2008; 122:71-7.
48. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci 2008;121(Pt 6):727-35.
49. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesen-chymal transition and enhances metastatic potential for epi-thelial ovarian carcinoma cells. Int J Oncol 2007;31:277-83.
50. Chen Y, Li L, Zeng J, Wu K, Zhou J, Guo P, et al. Twist confers chemoresistance to anthracyclines in bladder cancer through up-regulating P-glycoprotein. Chemotherapy 2012;58:264-72.